Niki BioSolutions Inc. Overview
Niki BioSolutions is a sub-$20M market-capitalization life-sciences company built from two components. The first is a dormant Hong Kong-rooted drug developer, legacy Aptorum. The second is DiamiR Biosciences, a small Princeton, New Jersey molecular-diagnostics company. The combined company describes itself as a clinical-stage life-sciences business that provides genomic and biomarker testing through a CLIA-certified, CAP-accredited laboratory, with a focus on brain health and oncology. Its strategic center of gravity is now DiamiR's proprietary plasma microRNA platform for early detection and monitoring of mild cognitive impairment, Alzheimer's, Parkinson's and cancer, plus a New York State-approved APOE genotyping test sold as a laboratory service. The legacy therapeutics, SACT-1 (neuroblastoma) and ALS-4 (anti-virulence for MRSA), have completed Phase 1 but are suspended until partners and funding are found. The company has no product revenue, carries going-concern doubt, depends on a $75M shelf, and is controlled by insiders. It is a high-risk, early-stage option on blood-based neurodegeneration diagnostics.
Company's own description (paraphrased from latest filings)
The September 18, 2026 Form S-3/A is the most recent comprehensive company description. It describes Niki as a clinical-stage life-sciences company that addresses unmet medical needs and provides genomic and biomarker testing to healthcare providers, research institutions and life-sciences organizations through its CLIA-certified, CAP-accredited laboratory. It says the company pairs proprietary technologies with scientific rigor to support precision medicine in brain health and oncology, and that it collaborates with academic centers, disease foundations and biopharma companies.
Legacy Aptorum's FY2025 Form 20-F (filed March 27, 2026) described a clinical-stage biopharmaceutical holding company. Its stated work was discovering, developing and commercializing therapeutic assets and diagnostic technologies, mainly in oncology (including orphan oncology indications) and infectious disease. Its lead projects were ALS-4 and SACT-1, with the PathsDxTest pathogen-identification platform co-developed with A*STAR's commercialization arm.
The S-3/A describes DiamiR as a molecular-diagnostics business. It is developing minimally invasive tests for early detection and monitoring of mild cognitive impairment (MCI), Alzheimer's, Parkinson's, other neurodegenerative diseases and cancer. The tests rest on quantitative analysis of circulating organ-enriched microRNAs (miRNAs) in plasma. The near-term objective is to launch laboratory-developed tests (LDTs) in DiamiR's CLIA-licensed laboratory, which could support patient screening and stratification as well as disease and treatment monitoring.
Independent characterization
| Layer | What it is | Economic status (Oct 2026) |
|---|---|---|
| Diagnostics services (DiamiR) | CLIA/CAP laboratory offering APOE genotyping and biomarker testing services to research sponsors and clinical research sites | Small, early revenue potential. DiamiR "has received revenue in the past" from testing services to life-sciences companies, but amounts are not publicly disclosed in sources reviewed |
| Diagnostics pipeline (DiamiR) | Plasma microRNA signatures for MCI/AD, Parkinson's, glioblastoma and other indications; planned LDTs | Pre-commercial; no product revenue |
| Therapeutics (legacy Aptorum) | SACT-1 (repurposed, neuroblastoma; orphan drug designation; 505(b)(2) pathway agreed with FDA); ALS-4 (anti-virulence small molecule, S. aureus/MRSA); preclinical follow-ons | Phase 1 completed (2022). R&D suspended since the YOOV deal collapsed in late 2024. Phase 2 contingent on partners/funding |
| Investments | $15.1M long-term investments carried at Dec 31, 2025 (composition not detailed in sources reviewed); Libra Sciences VIE (97.27% economic interest, not consolidated) | Non-cash, illiquid; drives most of book equity |
| Customer type | Example / evidence | End-market |
|---|---|---|
| Clinical research organizations / sites | Progressive Medical Research (APOE genotyping services agreement, Jul 23, 2026) | Alzheimer's clinical trials and translational research |
| Diagnostics/platform companies | Instant NanoBiosensors (validation of G8 APOE analyzer, Feb 2, 2026); AlzLabs Precision Diagnostics (biomarker data collaboration, Jun 22, 2026) | Blood-based brain-health testing |
| Academic centers | University of Pennsylvania (glioblastoma miRNA study, Mar 2026) | Neuro-oncology research |
| Biopharma | Historical testing services to life-sciences companies (S-3/A) | Drug development support |
| Grantors / foundations | DiamiR historically funded by government agencies and a private foundation (S-3/A) | Non-dilutive research funding |
| (Legacy) Hong Kong outpatients | AML Clinic / Talem Medical | Primary care services (discontinued) |
Niki is best understood as a holding company in transition with three economically distinct layers.
Business model and revenue mix. Legacy Aptorum's only revenue ever recorded came from healthcare services: an outpatient clinic in Hong Kong, the AML Clinic, operated as Talem Medical. That revenue was $1.54M in FY2021, $1.30M in FY2022 and $0.43M in FY2023, and nil in FY2024–FY2025 (FY2022 and FY2025 Form 20-F). Prospectively, the model is fee-for-service laboratory testing: APOE genotyping and biomarker panels for research sponsors and clinicians. Over time the company hopes to add higher-value proprietary LDTs and potential licensing or partnering income on the therapeutics. There is no subscription or product-sales revenue.
Value-chain position. In diagnostics, Niki sits at the assay-development and reference-laboratory stage. It runs tests in-house and validates third-party platforms, such as Instant NanoBiosensors' G8 analyzer. It does not manufacture in-vitro diagnostic kits. In therapeutics it is a virtual developer that relies on CROs (for example, Covar Pharmaceuticals) and licensors.
Customer types and end-markets.
Strategy
Stated strategy themes (paraphrased)
-
Pivot to precision diagnostics for brain health. Make DiamiR's plasma miRNA technology and CLIA/CAP lab the core of the business. Launch LDTs and use them for screening, stratification and monitoring in neurodegeneration (S-3/A, 2026).
-
Build a testing-services revenue base. Expand validated service offerings (APOE genotyping, protein biomarker panels) and lab throughput, including the automated INB platform validation (Feb 2026), the PMR services agreement (Jul 2026) and the AlzLabs data collaboration (Jun 2026).
-
Partner the legacy therapeutics. Advance ALS-4 to Phase 2 and SACT-1 to Phase 1/2 only with strategic collaborators who bring both money and clinical expertise (FY2025 20-F; S-3/A).
-
Collaborate with academia, foundations and biopharma to generate clinical validation and non-dilutive funding (S-3/A).
-
Normalize the corporate platform for U.S. capital markets. Delaware domestication, domestic SEC reporting, a $75M shelf, and investor-conference visibility (H.C. Wainwright, Sep 14, 2026; Lytham Partners, Sep 29–30, 2026).
Initiative register (last 24 months)
| Date | Initiative | Type | Detail |
|---|---|---|---|
| Jul 14, 2025 | DiamiR merger agreement plus Management Services Agreement and IP License | Transformation / M&A | The MSA and license gave Aptorum Therapeutics non-exclusive access to DiamiR IP for upfront and periodic payments and royalties until close. Both terminated at closing |
| Aug 21, 2025 | NYS approval of the APOE genotyping test | Product/regulatory | Enables testing of New York specimens |
| Oct 10, 2025 | Up to $6M RDO with warrants | Financing | $2M upfront plus up to $4M on warrant exercise at $2.00 (pre-split) |
| Nov 19, 2025 | Two CTAD 2025 abstracts | Scientific validation | Alzheimer's clinical-trials conference |
| Feb 2, 2026 | INB APOE platform validation | Partnership / capacity | Automation of APOE testing |
| Mar 10, 2026 | UPenn glioblastoma miRNA publication | Scientific validation | Extends the platform to neuro-oncology |
| Jun 22, 2026 | AlzLabs biomarker collaboration | Partnership | Protein plus miRNA data on amyloid-PET-characterized samples |
| Jul 2026 | Three AAIC 2026 presentations | Scientific validation | Alzheimer's Association International Conference |
| Jul 20, 2026 | 2026 Incentive Plan | Talent/compensation | Equity plan for the combined company |
| Jul 23, 2026 | PMR APOE testing services agreement | Commercial | First post-merger commercial agreement announced |
| Aug 28, 2026 | $75M universal shelf (S-3) | Financing | Baby-shelf limits apply; see Section 21 |
| Sep 2026 | Investor conference program | Capital markets | H.C. Wainwright (Sep 14); Lytham Partners (Sep 29–30) |
Sustainability/ESG commitments: none disclosed.
Cost programs: none announced formally. A de facto cost program (R&D suspension, headcount reduced to one) ran in 2023–2025.
Medium-term targets / guidance
The company has issued no quantitative revenue, margin, cash-runway or test-volume guidance in sources reviewed.
Products & Services
Diagnostics & laboratory services (DiamiR Biosciences)
| Offering | Description & capabilities | Target customer | Status / year | Pricing model |
|---|---|---|---|---|
| Plasma microRNA platform (proprietary) | Quantitative analysis of circulating organ-enriched miRNAs in plasma, intended for minimally invasive detection and monitoring of MCI, Alzheimer's, Parkinson's, other neurodegenerative diseases and cancer. Planned uses are screening, patient stratification and monitoring of disease and treatment | Neurologists, clinical-trial sponsors (enrichment/stratification), research institutions | Pre-commercial. LDTs planned in the CLIA lab (S-3/A, 2026) | — |
| APOE genotyping test | Identifies the ε2/ε3/ε4 alleles. ε4 is the strongest known genetic risk factor for late-onset Alzheimer's. Run in DiamiR's CLIA-certified, CAP-accredited lab | Clinical research sites, sponsors, clinicians | New York State approval announced Aug 21, 2025. Services agreement with Progressive Medical Research, Jul 23, 2026 | Fee-for-service; specific prices not disclosed |
| Automated APOE testing validation (with INB) | DiamiR compares Instant NanoBiosensors' automated G8 Genotyping Analyzer against its NYS-approved APOE test. Management expects higher testing capacity and lab throughput | Internal capacity; potential service expansion | Collaboration announced Feb 2, 2026; validation status not reported | — |
| Neurodegeneration biomarker data generation (with AlzLabs) | Measures protein biomarkers (p-Tau217, Aβ42/40, NfL and others) and miRNA in plasma samples with amyloid-PET-confirmed status | Diagnostic developers; future clinical panels | Collaboration announced Jun 22, 2026 | — |
| Glioblastoma miRNA biomarker research | miRNA biomarker study with the University of Pennsylvania, published in the journal Diagnostics | Neuro-oncology research | Publication announced Mar 10, 2026 | — |
| Contract testing services | Testing services for life-sciences companies | Biopharma | Historical; revenue amounts not disclosed (S-3/A) | — |
| Scientific presentations | Two abstracts at CTAD 2025 (Nov 2025); three presentations at AAIC 2026 (Jul 2026) | Scientific community | 2025–2026 | — |
Therapeutics (legacy Aptorum)
| Asset | Modality / mechanism | Indication | Development status | Regulatory notes |
|---|---|---|---|---|
| SACT-1 | Repurposed small-molecule drug | Neuroblastoma (pediatric); potentially other cancers | Phase 1 completed with positive results (2022); End-of-Phase-1 meeting with FDA completed. Phase 1/2 contingent on partnership and funding | FDA Orphan Drug Designation; FDA agreed to a 505(b)(2) pathway for a pediatric formulation (FY2025 20-F risk factors) |
| ALS-4 | First-in-class anti-virulence small molecule | S. aureus infections including MRSA. Aggregators also list M. tuberculosis and P. aeruginosa | Phase 1 completed with positive results (2022). Phase 2 contingent on partners and funding | Pre-IND discussions with FDA (2023) |
| SACT-COV19 | Repurposed small molecule | COVID-19 | Preclinical (aggregator description; likely inactive) | — |
| SACT-2, SACT-3 | Repurposed candidates | Oncology | Preclinical (aggregator description) | — |
| ALS-1 | Small molecule | S. aureus/MRSA infections | Preclinical (aggregator description) | — |
| ALS-2/3 | Small molecules | Gram-positive bacterial infections | Preclinical (aggregator description) | — |
| PathsDxTest (formerly RPIDD) | Molecular, NGS-based rapid pathogen identification from liquid biopsy | Infectious-disease diagnostics | Clinical validation studies reported in 2022; co-developed with Accelerate Technologies Pte Ltd (A*STAR commercialization arm). Current status not disclosed | — |
Important context. R&D was paused during the YOOV process and remained suspended after its termination (H1 2024 results release, Dec 2024). R&D spending fell from $10.87M in FY2021 to $0.35M in FY2025 (Form 20-F). The company has stated it is seeking strategic collaborators to provide financing and clinical expertise for ALS-4 Phase 2 and SACT-1 Phase 1/2 (FY2025 20-F; S-3/A).
Discontinued services
| Offering | Description | Status |
|---|---|---|
| AML Clinic (Talem Medical), Hong Kong | Outpatient medical clinic staffed by employed Hong Kong doctors | Revenue ceased after FY2023; operating entity struck off and dissolved (S-3/A) |
Financial Narrative
Sources: FY2022 Form 20-F (FY2021–FY2022 data); FY2023 Form 20-F (FY2023 balance sheet and cash flows); FY2025 Form 20-F (FY2023–FY2025 income statement; FY2024–FY2025 balance sheet and cash flows). All figures are in USD thousands unless stated. Per-share data are on the January 2023 reverse-split basis as reported. A separate row restates them for the July 2026 1-for-10 consolidation.
Income statement
No income tax expense was recorded in any year, so pre-tax income equals net income. The July-2026-restated EPS row is an analyst restatement (× 10); the aggregator AlphaQuery shows −$1.90 for FY2025, consistent with this.
Items not publicly disclosed in sources reviewed: EBITDA (depreciation and amortization was not separated in the retrieved statements, so EBITDA and EBITDA margin cannot be computed without estimation). Revenue-based margins for FY2024–FY2025 are not meaningful because revenue was zero.
Margins (revenue-bearing years only):
Revenue CAGR: FY2021–FY2023 was −47.1% per year. A five-year CAGR is not meaningful because revenue fell to zero.
Commentary. The income statement shows a managed wind-down rather than an operating business. Operating losses fell 91% between FY2021 and FY2025, from $19.2M to $1.8M. The drivers were the suspension of R&D (CRO spend fell from $1.39M in FY2023 to $0.17M in FY2024 per the FY2024 20-F), the reversal of deferred bonuses (FY2023), and reduction of headcount to one employee.
Reported net results were repeatedly flattered by non-operating items. FY2022 included a $5.59M gain on long-term investments. FY2023 included a $6.43M unrealized fair-value gain, without which the FY2023 net loss would have been ~$10.8M rather than $4.3M. FY2025 included a $0.69M warrant-liability fair-value gain. Legal and professional fees exceeded R&D in FY2025 ($1.06M versus $0.35M), reflecting merger costs. That is a clear inflection: the company spent more on transaction work than on science.
Interim data. H1 2025 net loss was $449,295, against $2,658,887 in H1 2024 (Form 6-K interim, via TipRanks/Barchart). H1 2026 net loss was $1.31M, with no revenue and $1.55M operating cash burn (company filing, as reported by BriefGlance, Sep 8, 2026). The H1 2026 figures predate the merger close.
Balance sheet
How the debt rows are built: total debt is bank loans plus convertible notes plus loans from related parties, excluding leases. FY2022 is a $3.0M bank loan plus $3.01M convertible notes plus $0.5M related-party loan. FY2023–FY2025 are convertible notes payable to a related party ($3.06M → $3.24M → $3.42M). Net debt is total debt less unrestricted cash.
The FY2025 balance sheet also carries a $306K warrant liability and $47K contingently redeemable warrants in temporary equity, both from the October 2025 offering. These are excluded from debt.
Balance-sheet commentary. The single most important feature is the $15.1M long-term investment, which is 81% of FY2025 total assets. The underlying investee(s) and valuation method are not described in the sources reviewed. The balance grew from $4.2M (FY2021) to $16.1M (FY2023) largely through fair-value gains, then took a $1.0M impairment in FY2024. Because attributable equity of $23.1M is mostly this illiquid asset, tangible liquid equity is very thin.
Liquidity is weak. FY2025 working capital was −$1.0M, and cash of $3.45M sat against $4.59M of current liabilities, including $3.42M of convertible notes owed to a related party. By June 30, 2026, cash had fallen to $1.83M and working-capital deficit had widened to −$2.48M (BriefGlance citing filings).
Negative non-controlling interests (−$9.4M) reflect accumulated losses absorbed by minority holders of subsidiaries and VIEs.
Post-merger: DiamiR's balance sheet, any purchase-price allocation, goodwill or intangibles from the acquisition, and pro forma combined figures were filed on the Form 8-K/A (event Aug 21, 2026).
Cash flow
Notes. Capital expenditure is not separately disclosed in the sources reviewed, so free cash flow cannot be calculated precisely. AlphaQuery reports FY2025 FCF of −$1.84M, equal to OCF, which implies negligible capex.
The FY2025 20-F narrative table shows the FY2025 net change in cash in parentheses as a decrease of $2,578,653. The balance sheet shows cash rising from $874K to $3,453K, an increase of the same amount, so the parenthesis appears to be a presentation error.
The FY2023 financing inflow was made up of: $1.6M ATM proceeds, $2.5M related-party loans, and $3.0M convertible notes, less $3.0M bank-loan repayment (FY2023 results release). The FY2025 financing inflow came from the January 2025 RDO ($3.0M gross) and October 2025 RDO ($2.0M gross upfront).
Commentary. Cash burn fell from $14.7M (FY2021) to ~$1.2–1.8M (FY2024–FY2025). Even that reduced burn has not been funded internally: every year required equity or related-party financing. The large FY2021 investing inflow ($16.5M) reflects liquidation of marketable securities and repayments of related-party loans, not operations.
Ratios
Not meaningful or not disclosed: net debt/EBITDA (EBITDA negative and D&A not disclosed); interest coverage (operating income negative in all years); cash conversion cycle (no meaningful receivables, inventory or payables cycle after FY2023).
Trend synthesis. Return metrics "improve" only because the denominator stayed propped up by the carried investment while losses shrank. They do not reflect better operating economics. The decisive inflections were:
-
FY2022: liquidity crisis, with working capital of −$5.4M and a bank loan plus convertible notes.
-
FY2023: recapitalization through ATM, related-party loans and converts.
-
FY2024: near-dormancy.
-
FY2025: merger-driven re-financing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare services revenue (USD K) | 1,542 | 1,296 | 431 | 0 | 0 |
Therapeutics revenue (USD K) | 0 | 0 | 0 | 0 | 0 |
Diagnostics revenue (USD K) | 0 | 0 | 0 | 0 | 0 |
Total revenue (USD K) | 1,542 | 1,296 | 431 | 0 | 0 |
Healthcare services share of revenue (%) | 100 | 100 | 100 | 0 | 0 |
Results by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare services gross profit (USD K) | 82 | 80 | 11 | 0 | 0 |
R&D expense, therapeutics and diagnostics (USD K) | 10,870 | 9,220 | 5,198 | 2,195 | 353 |
Group operating loss (USD K) | -19,207 | -17,509 | -10,724 | -3,941 | -1,818 |
Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Healthcare services gross margin (%) | 5.3 | 6.2 | 2.4 |
Healthcare services revenue YoY growth (%) | 69.1 | -15.9 | -66.7 |
Group Entities
| Entity | Role / status | Cumulative funding from parent (USD, through Sep 16, 2026) |
|---|---|---|
DiamiR Biosciences Corp. (Delaware) and DiamiR, LLC | Operating diagnostics subsidiary; CLIA/CAP lab | — |
Aptus Management Ltd | Group management/treasury | 64,309,273 |
Aptorum Therapeutics Ltd | Therapeutics holding; counterparty to the DiamiR MSA and license | 17,635,262 |
Acticule Life Sciences Ltd (80% owned) | ALS-series anti-infectives | 5,218,255 |
Aptorum Medical Ltd (90% owned) | Former HK clinic (Talem Medical); struck off/dissolved | 1,673,593 |
Aptorum Innovations Holding Pte (Singapore) | Diagnostics (PathsDx) holding | 442,202 |
Claves Life Sciences Ltd | Struck off/dissolved | 331,960 |
Signate Life Sciences Ltd | Struck off/dissolved | 319,386 |
Scipio Life Sciences Ltd | Controlled since Nov 2024 (former VIE) | 151,710 |
Aptorum Innovations Holding Ltd | Holding | 15,087 |
Aptorum Pharmaceutical Dev. Ltd | Development | 7,300 |
Aptorum Group LLC | U.S. entity | 4,338 |
Libra Sciences Ltd (VIE) | 97.27% economic interest / 31.51% voting; not consolidated | — |
Nativus Life Sciences, Videns Incorporation | Wholly owned subsidiaries (20-F definitions) | — |
Paths Diagnostics Pte. Ltd | PathsDxTest platform (per FY2024 filing summary) | — |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (USD K) | 1,542 | 1,296 | 431 | 0 | 0 |
Cost of healthcare services (USD K) | 1,460 | 1,216 | 421 | 0 | 0 |
Gross profit (USD K) | 82 | 80 | 11 | 0 | 0 |
R&D expense (USD K) | 10,870 | 9,220 | 5,198 | 2,195 | 353 |
General & administrative (USD K) | 5,409 | 5,220 | 1,931 | 669 | 573 |
Legal & professional fees (USD K) | 2,618 | 2,888 | 2,538 | 803 | 1,062 |
Other operating expense, net of income (USD K) | 393 | 261 | 1,068 | 273 | -171 |
Total operating expenses incl. cost of services (USD K) | 20,749 | 18,805 | 11,156 | 3,941 | 1,818 |
Operating income (USD K) | -19,207 | -17,509 | -10,724 | -3,941 | -1,818 |
Total other income/(expense), net (USD K) | -7,907 | 5,984 | 6,383 | -217 | 441 |
Pre-tax income (USD K) | -27,114 | -11,525 | -4,341 | -4,158 | -1,376 |
Net income, total (USD K) | -27,114 | -11,525 | -4,341 | -4,158 | -1,376 |
Net income attributable to company (USD K) | -25,048 | -9,800 | -2,825 | -4,268 | -1,363 |
EPS basic, as reported (USD) | -7.15 | -2.75 | -0.62 | -0.78 | -0.19 |
EPS diluted, as reported (USD) | -7.15 | -2.75 | -0.62 | -0.78 | -0.19 |
EPS basic, restated for Jul-2026 1:10 consolidation (USD) | -71.50 | -27.50 | -6.20 | -7.80 | -1.90 |
Weighted avg. basic shares, as reported (K) | 3,503 | 3,569 | 4,521 | 5,453 | 7,352 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Gross margin (%) | 5.3 | 6.2 | 2.4 |
Operating margin (%) | -1,245.6 | -1,351.0 | -2,486.0 |
Net margin, total net loss / revenue (%) | -1,758.6 | -889.3 | -1,006.3 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gain/(loss) on marketable securities (USD K) | -8,032 | -134 | -9 | 0 | 0 |
Gain on / fair-value change of long-term investments (USD K) | 0 | 5,588 | 6,431 | 0 | 0 |
Impairment of long-term investments (USD K) | 0 | 0 | -77 | -1,000 | 0 |
Government subsidies (USD K) | 0 | 0 | 123 | 928 | 0 |
Change in fair value of warrant liability (USD K) | 0 | 0 | 0 | 0 | 690 |
Interest income/(expense), net (USD K) | -94 | 147 | -121 | -147 | -96 |
Balance Sheet — Total assets
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (USD K) | 21,907 | 20,867 | 20,640 | 16,130 | 18,691 |
Cash and cash equivalents (USD K) | 8,131 | 1,883 | 2,005 | 874 | 3,453 |
Restricted cash (USD K) | 130 | 3,130 | 0 | 0 | 0 |
Current assets (USD K) | 12,688 | 7,068 | 2,476 | 960 | 3,593 |
Current liabilities (USD K) | 4,377 | 12,503 | 2,099 | 4,339 | 4,594 |
Working capital (USD K) | 8,311 | -5,435 | 377 | -3,379 | -1,001 |
Long-term investments (USD K) | 4,157 | 9,745 | 16,099 | 15,099 | 15,099 |
Property and equipment, net (USD K) | 3,731 | 2,825 | 1,664 | 0 | 0 |
Intangible assets, net (USD K) | 880 | 753 | 147 | 0 | 0 |
Goodwill (USD K) | 0 | 0 | 0 | 0 | 0 |
Short-term debt (USD K) | 0 | 6,013 | 3,059 | 3,239 | 3,419 |
Long-term debt (USD K) | 0 | 500 | 0 | 0 | 0 |
Total debt (USD K) | 0 | 6,513 | 3,059 | 3,239 | 3,419 |
Net debt (USD K) | -8,131 | 4,630 | 1,054 | 2,365 | -34 |
Total liabilities (USD K) | 4,401 | 13,034 | 5,257 | 4,353 | 4,900 |
Equity attributable to company (USD K) | 23,607 | 15,712 | 24,846 | 21,135 | 23,115 |
Non-controlling interests (USD K) | -6,101 | -7,879 | -9,463 | -9,357 | -9,371 |
Total equity (USD K) | 17,506 | 7,833 | 15,383 | 11,777 | 13,745 |
Accumulated deficit (USD K) | -55,538 | -65,337 | -68,162 | -72,430 | -73,793 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (USD K) | -14,652 | -12,319 | -7,724 | -1,190 | -1,837 |
Investing cash flow (USD K) | 16,507 | 2,445 | 625 | 59 | 0 |
Financing cash flow (USD K) | 2,781 | 6,625 | 4,092 | 0 | 4,415 |
Net change in cash incl. restricted (USD K) | 4,636 | -3,249 | -3,008 | -1,131 | 2,579 |
Dividends paid (USD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD K) | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Current ratio (x) | 2.90 | 0.57 | 1.18 | 0.22 | 0.78 |
Debt to total equity (x) | 0.00 | 0.83 | 0.20 | 0.28 | 0.25 |
ROIC, operating loss / year-end invested capital (%) | -204.9 | -140.5 | -65.2 | -27.9 | -13.3 |
Asset turnover, revenue / year-end assets (x) | 0.07 | 0.06 | 0.02 | 0 | 0 |
Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, attributable net loss / avg attributable equity (%) | -49.8 | -13.9 | -18.6 | -6.2 |
ROA, total net loss / avg total assets (%) | -53.9 | -20.9 | -22.6 | -7.9 |
Revenue by Region
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong revenue (USD K) | 1,542 | 1,296 | 431 | 0 | 0 |
United States revenue (USD K) | 0 | 0 | 0 | 0 | 0 |
Europe/UK revenue (USD K) | 0 | 0 | 0 | 0 | 0 |
Rest of world revenue (USD K) | 0 | 0 | 0 | 0 | 0 |
Region Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Hong Kong revenue YoY growth (%) | -15.9 | -66.7 | -100.0 |
Share Price & Returns
| Date | Close (USD) | Notes | Source |
|---|---|---|---|
Jul 22, 2026 | 8.99 | Two days after NIKI debut | MarketChameleon |
Aug 21, 2026 | 8.58 | — | MarketChameleon |
Aug 28, 2026 | 6.90 | Shelf filed same day | StockAnalysis |
Sep 4, 2026 | 6.20 | Intraday range 6.05–9.68; volume 4.14M versus ~152K average | Benzinga; Yahoo |
Sep 9, 2026 | 6.01 | — | Benzinga |
Sep 16, 2026 | 4.77 | Used for S-3/A public-float calculation | S-3/A |
Sep 18, 2026 | 4.72 | Latest verified close | Benzinga |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalization | ~USD 13.2M | 2,793,591 shares × $4.72 (Sep 18, 2026); analyst calculation |
Enterprise value (indicative) | ~USD 14.8M | Market cap + $3.42M related-party convertible notes (Dec 31, 2025) − $1.83M cash (Jun 30, 2026). Mixed dates; indicative only |
P/E | n/m | Losses |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | Zero revenue |
P/B (indicative) | ~0.57x | Market cap ÷ legacy Aptorum attributable equity of $23.1M (Dec 31, 2025). Excludes DiamiR's post-merger book value and is inflated by the illiquid $15.1M investment |
Peer multiples | Not computed. | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus / price targets | None; Benzinga reports no analyst price target |
Dividend history and policy | Never paid. No dividend policy; earnings to be retained (S-3/A) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Shelf capacity | $75M S-3, limited by General Instruction I.B.6 to one-third of public float per 12 months while float is below $75M. That is about $1.7M on a ~$5.04M float (analyst calculation from S-3/A) |
Equity incentive plan | 2026 Incentive Plan (pool size not disclosed in sources reviewed) |
Warrants outstanding | Warrants from the Oct 2025 RDO (up to 2,000,000 pre-split at $2.00, i.e. ~200,000 at ~$20.00 post-split; analyst adjustment, terms subject to warrant anti-dilution provisions). Carried as a $306K liability plus $47K temporary equity at Dec 31, 2025 |
Capital Instruments
| Instrument | Amount (Dec 31, 2025) | Classification | Maturity / terms |
|---|---|---|---|
Convertible notes to a related party | USD 3,418,500 | Current | Within 12 months (classified current); interest rate and conversion terms not disclosed in sources reviewed |
Amounts due to related parties | USD 79,180 | Current | On demand |
Bank debt | Nil | — | $3.0M bank loan repaid in FY2023 |
Analyst Conclusions
Management guidance and consensus
Management guidance: none quantitative. Qualitative priorities are LDT development, expanding testing services, validation collaborations, and partnering the therapeutics (S-3/A; 2026 releases).
Consensus: no sell-side coverage; no consensus estimates exist.
Bull case
-
A real, regulated revenue engine exists from day one. A CLIA/CAP lab with an NYS-approved APOE test and a signed sponsor agreement (PMR) offers an early, low-capex path to services revenue. Sponsor-driven APOE demand is structural in the anti-amyloid era.
-
Valuation is a fraction of book and of strategic replacement cost. At ~$13M market cap against $23.1M legacy attributable equity, the market assigns little value to the miRNA platform, the lab or two Phase-1-complete assets (one with orphan designation).
-
Scientific momentum is building. Two CTAD 2025 abstracts, three AAIC 2026 presentations, a peer-reviewed glioblastoma paper, and a head-to-head biomarker study against PET-confirmed status (AlzLabs) are the kind of data that could attract a partner or acquirer.
Bear case
-
Survival financing will be highly dilutive. Cash was $1.83M at June 30, 2026 against a $1.55M half-year burn before adding DiamiR's costs. Both entities carry going-concern opinions. The baby-shelf cap (~$1.7M per 12 months on the current float) means repeated small raises, warrant-heavy structures or related-party funding.
-
Competitive irrelevance risk. The AD blood-test market is coalescing around protein p-Tau217 assays from heavily capitalized players. APOE genotyping is a commodity at Quest and Labcorp. miRNA signatures must clear a high evidentiary bar before payers or clinicians adopt them.
-
Governance and structure discount. A 51.56% controlling holder, combined Chair/CEO, related-party convertible debt, an opaque $15.1M investment, Hong Kong/PRC regulatory overlays, and a history of failed and completed reverse mergers and two reverse splits in 3.5 years all argue for a persistent discount.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters |
|---|---|
| First 10-Q/10-K as combined company | First disclosure of consolidated cash, burn, DiamiR revenue, goodwill and intangibles |
| Financing under the $75M shelf (size, price, warrants) | Dilution and runway |
| Nasdaq compliance status (bid price, stockholders' equity) | Listing continuity |
| New services agreements and test-volume disclosures | Evidence of a revenue trajectory |
| AlzLabs and INB study readouts | Platform validation; lab throughput |
| LDT launch for miRNA brain-health signature | Transition from services to proprietary tests |
| Partnering or out-licensing of SACT-1 or ALS-4 | Non-dilutive capital; asset value realization |
| Clarity on the $15.1M long-term investment | Asset quality; potential monetization |
| First DEF 14A | Compensation, committees and ownership transparency |
| Hong Kong/PRC regulatory developments | HFCAA/CSRC exposure |
Analyst verdict
Niki BioSolutions is not an operating company in the conventional sense yet. It is a recapitalized listed vehicle wrapped around a very small U.S. diagnostics laboratory and a shelf of suspended drug programs. Legacy Aptorum's record over FY2021–FY2025 is one of steady retrenchment. Operating losses fell from $19.2M to $1.8M, but revenue went to zero, headcount went to one, and survival depended on equity issuance, related-party convertible notes and non-cash fair-value gains. The DiamiR merger changes the narrative, not yet the numbers. It brings a CLIA/CAP lab, an NYS-approved APOE test, a nascent sponsor customer base and a differentiated microRNA platform with credible scientific activity in 2025–2026.
The investment question is binary and financing-led. On the positive side, the company is priced at roughly $13M, below the book value carried in legacy Aptorum's last balance sheet, and its regulated lab gives it a services foothold in a growing Alzheimer's testing ecosystem. On the negative side, liquidity is critical: $1.83M of cash at mid-2026, going-concern language at parent and subsidiary, and a baby-shelf constraint that caps registered primary issuance at roughly $1.7M a year at the current float. Most realistic funding paths are therefore dilutive or related-party-dependent. Competitive dynamics are also unforgiving. Protein p-Tau217 tests from well-funded incumbents set the standard against which any miRNA approach must prove incremental value, and APOE genotyping is commoditized.
Governance warrants a discount: a controlling holder, combined Chair/CEO, an opaque $15.1M investment, and residual Hong Kong regulatory exposure. Verdict: speculative, high-risk; suitable only as a small, event-driven position. The key monitorables are the first consolidated 10-Q, the terms of the next financing, disclosed test volumes or revenue from DiamiR's services, and any partnering of SACT-1 or ALS-4. Absent a non-dilutive partnership or clear services-revenue traction within 12 months, the base case is continued dilution and listing-compliance pressure.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Background (as available) | Tenure notes |
|---|---|---|---|
Ian Huen | Chairman; signs filings as Chief Executive Officer | Founder and long-time controlling shareholder of Aptorum. 100% owner of Jurchen Investment Corporation, which owns 76.8% of Aeneas Limited (Aeneas Group) | Director since Aptorum's formation; CEO by 2024. Inconsistency: the FY2025 20-F definitions describe him as "former CEO," while the Jul 2026 8-K and Sep 2026 S-3/A identify him as CEO |
Kira S. Sheinerman, Ph.D. | Director | DiamiR co-founder; reported 51.56% beneficial owner of Niki common stock | Joined at merger close |
Justin Wu | Independent Director | — | Carried over from Aptorum board |
Douglas Arner | Independent Director | — | Carried over from Aptorum board |
Laura A. Philips | Independent Director | — | Joined at merger close |
Alidad Mireskandari, Ph.D. | Board Observer; President & COO | Former CEO of DiamiR (quoted as such in the Jun 22, 2026 release). Presented the company at the H.C. Wainwright conference on Sep 14, 2026 | Observer since merger close |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Ian Huen | Chief Executive Officer (per S-3/A agent for service) | Also Chairman, which means CEO and Chair roles are not separated |
Alidad Mireskandari, Ph.D. | President & Chief Operating Officer | Operating lead for the DiamiR business |
Darren Lui | Former CEO & Executive Director (FY2022 period) | Departure date not confirmed in sources reviewed |
Major Shareholders
| Holder | Stake | Source / notes |
|---|---|---|
Kira S. Sheinerman | 51.56% beneficial ownership of common stock | BriefGlance, Sep 8, 2026, citing company filings |
Ian Huen / Jurchen Investment Corporation | Not precisely disclosed in sources reviewed. Pre-merger Jurchen controlled Aptorum through Class B shares (1,796,934 pre-split). Each Class B share converted into one common share plus one Series A Preferred share, so Jurchen's post-merger common stake is at least ~179,693 shares (~6.4%) if Jurchen held all Class B. Unconfirmed | Form 8-K; FY2025 20-F |
All affiliates combined | ~62% (2,793,591 total common − 1,056,729 non-affiliate shares = ~1,736,862 affiliate shares) | Analyst calculation from S-3/A and 8-K |
Public float | ~1.06M shares (~38%) | S-3/A |
Top-10 institutional holders | Not publicly disclosed in sources reviewed. Given a ~$5M non-affiliate float, institutional ownership is likely de minimis | — |
Series A Preferred (179,693 shares) | Held by former Aptorum Class B holders. Non-voting, non-convertible, non-redeemable. Entitled to a share of sale or liquidation proceeds under the merger's 70/30 allocation | Form 8-K (Series A COD) |
Board & Management Changes
| Date | Change |
|---|---|
Oct 9, 2025 | Aptorum announced it would expand its board and management with executives in connection with the DiamiR merger |
Jul 20, 2026 | New board seated (Sheinerman and Philips added; Mireskandari as observer). Voting and Support Agreement and Stockholder Agreement executed. The final Stockholder Agreement lowered the ownership threshold required to be a signatory |
Sep 2026 | Mireskandari publicly titled President & COO (H.C. Wainwright conference release, Sep 8, 2026) |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | Relevant offering | Relative positioning vs Niki |
|---|---|---|---|
Blood-based Alzheimer's diagnostics | C2N Diagnostics (private) | PrecivityAD2 (plasma p-Tau217/Aβ42/40) | Commercial leader in U.S. specialty AD blood testing; far ahead on validation and payer engagement |
Blood-based Alzheimer's diagnostics | Quanterix (Nasdaq: QTRX) | Simoa p-Tau217 and LucentAD assays; NfL | Platform and assay vendor with an installed base. |
Blood-based Alzheimer's diagnostics | Fujirebio (H.U. Group) | — | Regulated IVD with automation scale |
Blood-based Alzheimer's diagnostics | Roche Diagnostics | Elecsys plasma p-Tau assays | Global IVD incumbent |
Reference lab testing (AD panels, APOE) | Quest Diagnostics (NYSE: DGX) | AD-Detect panels; APOE genotyping | National reference-lab scale; APOE is commoditized there |
Reference lab testing (AD panels, APOE) | Labcorp (NYSE: LH) | ATN profile; APOE genotyping | National scale; payer contracts |
AD biomarker technology | ALZpath (private) | p-Tau217 antibody/assay technology | Technology licensor to labs |
microRNA diagnostics | MiRXES (Singapore) | miRNA-based cancer screening tests | More advanced commercial miRNA franchise |
microRNA diagnostics | Hummingbird Diagnostics (Germany) | Blood small-RNA signature diagnostics | Direct technology peer, private |
Neuroblastoma therapeutics (vs SACT-1) | United Therapeutics (Unituxin, dinutuximab) | Approved anti-GD2 antibody | Standard-of-care incumbent |
Neuroblastoma therapeutics (vs SACT-1) | Y-mAbs Therapeutics (Danyelza, naxitamab) | Approved anti-GD2 antibody | Approved competitor |
Neuroblastoma therapeutics (vs SACT-1) | US WorldMeds (Iwilfin, eflornithine) | Approved maintenance therapy (FDA 2023) | Approved oral therapy in an adjacent setting |
MRSA / anti-infectives (vs ALS-4) | Generic and branded anti-MRSA antibiotics (vancomycin, linezolid, daptomycin) | Approved antibiotics | Entrenched, low-cost standard of care |
Peer Comparison FY2025
| Metric | Niki BioSolutions (legacy FY2025) | Quanterix (FY2024) | Quest Diagnostics (FY2024) | Labcorp (FY2024) |
|---|---|---|---|---|
Revenue | USD 0 | ~USD 137M | ~USD 9.9B | ~USD 13.0B |
Revenue growth | n/m (−100% vs FY2023) | — | — | — |
Operating margin | n/m (operating loss USD 1.8M) | — | — | — |
R&D intensity | n/m (R&D USD 0.35M) | — | — | — |



